


CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-3. (canceled)


4. (currently amended) A crystalline ethyl acetate solvate of carvedilol characterized by a PXRD pattern having peaks at about 5.8, 6.5, 7.3, 10.7, 11.1, 11.5, 13.1, 13.7, 16.0, 16.8, 17.7, 18.5, 23.0, and 30.5 ± 0.2 degrees two-theta wherein the PXRD pattern is substantially as follows:



in Figure 1.

5. (canceled)


6. (currently amended) A crystalline ethyl acetate solvate of carvedilol characterized by a PXRD pattern having peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta and a DSC thermogram having peaks at about 74° C and 112° C wherein the DSC thermogram is substantially as follows:




in Figure 2.

7-8. (canceled)

9. (currently amended) A crystalline ethyl acetate solvate of carvedilol characterized by a PXRD pattern having peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta and a DSC thermogram having peaks at about 74° C and 112° C wherein the DSC thermogram is substantially as follows:



in Figure 2 and further characterized by a FTIR spectrum having peaks at about 613, 720, 740, 994, 1100, 1125, 1228, 1257, 1286, 1441, 1454, 1508, 1589, 1737, 2840, 2911, 2935, 3281, 3389, and 3470 cm^{-1} wherein the FTIR spectrum is substantially as follows:



in Figure 4.

10-29. (canceled)